HemoGenyx Pharmaceuticals (LSE:HEMO) PLC said a "significant" application made with the United States Patent and Trademark Office has been approved to protect its CDX antibody technology.
The patent application, entitled 'Method of Eliminating Hematopoietic Stem Cells/Hematopoietic Progenitors (HSC/HP) In A Patient Using Bi-Specific Antibodies', was approved to be issued as a patent.
Chief executive Vladislav Sandler said: "This is a significant addition to the patent protection for CDX which remains one of our key product candidates for the future.
"This also solidifies our company's position as a leader in the area of conditioning bone marrow transplants."